Live progression free from multiple myeloma longer.

NEW COMBINATION: SARCLISA + Kyprolis® (carfilzomib) and dexamethasone

Learn more

Going progression free longer means going longer without your Multiple Myeloma getting worse

In a clinical study, SARCLISA given with Pomalyst® (pomalidomide) and dexamethasone (Pd) extended the time people lived without their multiple myeloma getting worse compared to Pd alone (median of 11.5 months vs 6.5 months).

SARCLISA trial results

SARCLISA was
proven in a Phase 3 study.

See the Results

Target icon

SARCLISA is a targeted
immunotherapy that works
together with your
immune system.

See How It Works

CareASSIST logo

CareASSIST helps eligible patients with access and support for SARCLISA.

Find Out More

Play icon

SARCLISA Stories

Hear stories from people who are living with relapsed refractory Multiple Myeloma or caring for someone who is.